Applicant: SCLAVO BIOCINE SPA [IT]; The activity of inhibitors of vacuolar-type H+-ATPases in the inhibition of vacuolation induced by (Helicobacter pylori) is disclosed. Preferred agents are the macrolide antibiotics bafilomycins A1, A2, B1, B2, C1, C2 and D, especially bafilomycin A1. The use of such compounds in the treatment of diseases, including peptic ulceration, is claimed. The activity of inhibitors of vacuolar-type H<+>-ATPases in the inhibition of vacuolation induced by Helicobacter pylori is disclosed. Preferred agents are the macrolide antibiotics bafilomycins A1, A2, B1, B2, C1, C2 and D, especially bafilomycin A1. The use of such compounds in the treatment of diseases, including peptic ulceration, is claimed.
USE OF INHIBITORS OF VACUOLAR-TYPE H<+> ATPASES
MONTECUCCO, CESARE;PAPINI, EMANUELE;
1994
Abstract
Applicant: SCLAVO BIOCINE SPA [IT]; The activity of inhibitors of vacuolar-type H+-ATPases in the inhibition of vacuolation induced by (Helicobacter pylori) is disclosed. Preferred agents are the macrolide antibiotics bafilomycins A1, A2, B1, B2, C1, C2 and D, especially bafilomycin A1. The use of such compounds in the treatment of diseases, including peptic ulceration, is claimed. The activity of inhibitors of vacuolar-type H<+>-ATPases in the inhibition of vacuolation induced by Helicobacter pylori is disclosed. Preferred agents are the macrolide antibiotics bafilomycins A1, A2, B1, B2, C1, C2 and D, especially bafilomycin A1. The use of such compounds in the treatment of diseases, including peptic ulceration, is claimed.Pubblicazioni consigliate
I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
